Investigation of serum BDNF levels in drug-naive patients with schizophrenia

E. N. Rizos; I. Rontos; E. Laskos; G. Arsenis; P. G. Michalopoulou; D. Vasilopoulos; R. Gournellis; L. Lykouras

doi:10.1016/j.pnpbp.2008.04.007

Investigation of serum BDNF levels in drug-naive patients with schizophrenia

E. N. Rizos, I. Rontos, E. Laskos, G. Arsenis, P. G. Michalopoulou, D. Vasilopoulos, R. Gournellis, L. Lykouras

Psychosis Studies

Research output: Contribution to journal › Literature review › peer-review

104 Citations (Scopus)

Abstract

The role of brain-derived neurotrophic factor (BDNF) is to promote and modulate the neuronal responses across neurotransmitter systems in the brain. Therefore, abnormal BDNF signaling may be associated with the pathophysiology of schizophrenia. Decreased BDNF levels in the brain and the serum of patients with psychotic disorders have been reported. In the present study, we assessed serum BDNF levels in a group of 14 drug-naive first-episode patients with schizophrenia (FEP), compared to 15 healthy controls. The serum BDNF levels in the sample of FEP patients was significantly reduced compared to normal controls (23.92 +/- 5.99 ng/ml vs. 30.0 +/- 8.43 ng/ml, F=5.01, df=1, p=.034). Negative correlations were shown between serum BDNF levels of the patients and the PANSS Positive and Negative subscale scores. Our findings indicate that BDNF levels at the onset of schizophrenia may reflect associated pathophysiological processes as well as the severity of positive and negative psychotic symptoms.

Original language	English
Article number	N/A
Pages (from-to)	1308-1311
Number of pages	4
Journal	Progress in Neuro-Psychopharmacology & Biological Psychiatry
Volume	32
Issue number	5
DOIs	https://doi.org/10.1016/j.pnpbp.2008.04.007
Publication status	Published - 1 Jul 2008

Access to Document

10.1016/j.pnpbp.2008.04.007

Cite this

@article{e5698466cc7b427e9f39f013a30d6634,

title = "Investigation of serum BDNF levels in drug-naive patients with schizophrenia",

abstract = "The role of brain-derived neurotrophic factor (BDNF) is to promote and modulate the neuronal responses across neurotransmitter systems in the brain. Therefore, abnormal BDNF signaling may be associated with the pathophysiology of schizophrenia. Decreased BDNF levels in the brain and the serum of patients with psychotic disorders have been reported. In the present study, we assessed serum BDNF levels in a group of 14 drug-naive first-episode patients with schizophrenia (FEP), compared to 15 healthy controls. The serum BDNF levels in the sample of FEP patients was significantly reduced compared to normal controls (23.92 +/- 5.99 ng/ml vs. 30.0 +/- 8.43 ng/ml, F=5.01, df=1, p=.034). Negative correlations were shown between serum BDNF levels of the patients and the PANSS Positive and Negative subscale scores. Our findings indicate that BDNF levels at the onset of schizophrenia may reflect associated pathophysiological processes as well as the severity of positive and negative psychotic symptoms.",

author = "Rizos, {E. N.} and I. Rontos and E. Laskos and G. Arsenis and Michalopoulou, {P. G.} and D. Vasilopoulos and R. Gournellis and L. Lykouras",

year = "2008",

month = jul,

day = "1",

doi = "10.1016/j.pnpbp.2008.04.007",

language = "English",

volume = "32",

pages = "1308--1311",

journal = "Progress in Neuro-Psychopharmacology & Biological Psychiatry",

issn = "0278-5846",

publisher = "Elsevier Inc.",

number = "5",

}

TY - JOUR

T1 - Investigation of serum BDNF levels in drug-naive patients with schizophrenia

AU - Rizos, E. N.

AU - Rontos, I.

AU - Laskos, E.

AU - Arsenis, G.

AU - Michalopoulou, P. G.

AU - Vasilopoulos, D.

AU - Gournellis, R.

AU - Lykouras, L.

PY - 2008/7/1

Y1 - 2008/7/1

N2 - The role of brain-derived neurotrophic factor (BDNF) is to promote and modulate the neuronal responses across neurotransmitter systems in the brain. Therefore, abnormal BDNF signaling may be associated with the pathophysiology of schizophrenia. Decreased BDNF levels in the brain and the serum of patients with psychotic disorders have been reported. In the present study, we assessed serum BDNF levels in a group of 14 drug-naive first-episode patients with schizophrenia (FEP), compared to 15 healthy controls. The serum BDNF levels in the sample of FEP patients was significantly reduced compared to normal controls (23.92 +/- 5.99 ng/ml vs. 30.0 +/- 8.43 ng/ml, F=5.01, df=1, p=.034). Negative correlations were shown between serum BDNF levels of the patients and the PANSS Positive and Negative subscale scores. Our findings indicate that BDNF levels at the onset of schizophrenia may reflect associated pathophysiological processes as well as the severity of positive and negative psychotic symptoms.

AB - The role of brain-derived neurotrophic factor (BDNF) is to promote and modulate the neuronal responses across neurotransmitter systems in the brain. Therefore, abnormal BDNF signaling may be associated with the pathophysiology of schizophrenia. Decreased BDNF levels in the brain and the serum of patients with psychotic disorders have been reported. In the present study, we assessed serum BDNF levels in a group of 14 drug-naive first-episode patients with schizophrenia (FEP), compared to 15 healthy controls. The serum BDNF levels in the sample of FEP patients was significantly reduced compared to normal controls (23.92 +/- 5.99 ng/ml vs. 30.0 +/- 8.43 ng/ml, F=5.01, df=1, p=.034). Negative correlations were shown between serum BDNF levels of the patients and the PANSS Positive and Negative subscale scores. Our findings indicate that BDNF levels at the onset of schizophrenia may reflect associated pathophysiological processes as well as the severity of positive and negative psychotic symptoms.

U2 - 10.1016/j.pnpbp.2008.04.007

DO - 10.1016/j.pnpbp.2008.04.007

M3 - Literature review

SN - 0278-5846

VL - 32

SP - 1308

EP - 1311

JO - Progress in Neuro-Psychopharmacology & Biological Psychiatry

JF - Progress in Neuro-Psychopharmacology & Biological Psychiatry

IS - 5

M1 - N/A

ER -

Investigation of serum BDNF levels in drug-naive patients with schizophrenia

Abstract

Access to Document

Fingerprint

Cite this